Related Experiment Video
Updated: Aug 17, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Yakov Chudnovsky1, Amy E Adams, Paul B Robbins
1Veterans Affairs Palo Alto Healthcare System, Palo Alto, California 94304, USA.
Abstract:
Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence. These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide 3-kinase (PI3K). Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplification. Activation of PI3K pathway components occurs by PTEN loss and by AKT3 amplification. Melanomas also commonly show impairment of the p16(INK4A)-CDK4-Rb and ARF-HDM2-p53 tumor suppressor pathways. CDKN2A mutations can produce p16(INK4A) and ARF protein loss. Rb bypass can also occur through activating CDK4 mutations as well as by CDK4 amplification. In addition to ARF deletion, p53 pathway disruption can result from dominant negative TP53 mutations. TERT amplification also occurs in melanoma. The extent to which these mutations can induce human melanocytic neoplasia is unknown. Here we characterize pathways sufficient to generate human melanocytic neoplasia and show that genetically altered human tissue facilitates functional analysis of mutations observed in human tumors.
Insights
This study identifies key genetic pathways sufficient to cause melanoma, a growing skin cancer. Understanding these alterations in human tissue aids in analyzing tumor mutations.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Melanoma incidence is rising, driven by multiple genetic alterations.
- Key pathways involved include Ras/Raf, phosphoinositide 3-kinase (PI3K), and tumor suppressor pathways like p16(INK4A)-CDK4-Rb and ARF-HDM2-p53.
- Specific genetic events include mutations (N-Ras, B-Raf, TP53), amplifications (AKT3, CDK4, TERT), and deletions (PTEN, CDKN2A).
Purpose of the Study:
- To characterize genetic pathways sufficient for inducing human melanocytic neoplasia.
- To demonstrate that genetically altered human tissue can facilitate functional analysis of melanoma mutations.
Main Methods:
- Analysis of genetic alterations in melanoma, including mutations, amplifications, and deletions.
- Characterization of affected signaling pathways (Ras, Raf, PI3K, p53, Rb).
- Utilizing genetically altered human tissue for functional studies.
Main Results:
- Identified multiple genetic alterations converging on Ras, Raf, and PI3K pathways.
- Demonstrated impairment of critical tumor suppressor pathways (p16(INK4A)-CDK4-Rb, ARF-HDM2-p53).
- Showcased the utility of genetically modified human tissue for studying melanoma pathogenesis.
Conclusions:
- Specific combinations of genetic alterations are sufficient to drive human melanocytic neoplasia.
- Genetically altered human tissue models are valuable tools for understanding melanoma development and mutation function.
